Pharma Reviews: Lupin no longer bullish on Japanese market as price rules prove a dampener

Pharmaceuticals major Lupin stayed invested in Japan when most Indian peers quit. Its Japanese subsidiary has grown at a 15 per cent compound ...
Read more: Lupin no longer bullish on Japanese market as price rules prove a dampener